Development of 99mTc-EC-tyrosine for Early Detection of Breast Cancer Tumor Response to the Anticancer Drug Melphalan

Academic Radiology

Volumn 20, Issue 1, 2013, Pages 41-51

  Kong, Fan Lin ^a   Zhang, YinHan ^a   Young, Daniel P ^a   Yu, Dong Fang ^a   Yang, David J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Amino acid transporter; Breast cancer; EC tyrosine; Melphalan; Planar imaging

Indexed keywords

AMINO ACID TRANSPORTER; KI 67 ANTIGEN; MELPHALAN; N,N' ETHYLENE DI LEVO CYSTEINE TYROSINE TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SIZE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE DISTRIBUTION; TREATMENT RESPONSE;

AMINO ACID TRANSPORT SYSTEM Y+L; ANIMALS; BREAST NEOPLASMS; CHELATING AGENTS; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MELPHALAN; NEOPLASM PROTEINS; ORGANOTECHNETIUM COMPOUNDS; RATS; RATS, INBRED F344; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TYROSINE;

EID: 84870952570     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2012.08.005     Document Type: Article

References (24)

1. Rosenbaum S.J., Lind T., Antoch G., et al. False-positive FDG PET uptake-the role of PET/CT. Eur Radiol 2006, 16:1054-1065.
2. Lim H.S., Yoon W., Chung T.W., et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007, 27(suppl):S197-S213.
3. Aukema T.S., Rutgers E.J., Vogel W.V., et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 2010, 36:387-392.
4. Jager P.L., Vaalburg W., Pruim J., et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001, 42:432-445.
5. McConathy J., Goodman M.M. Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev 2008, 27:555-573.
6. Kole A.C., Nieweg O.E., Pruim J., et al. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET. J Nucl Med 1997, 38:692-696.
7. Kaira K., Oriuchi N., Imai H., et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 2009, 100:248-254.
8. Furuya M., Horiguchi J., Nakajima H., et al. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 2012, 103:382-389.
9. del Amo E.M., Urtti A., Yliperttula M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 2008, 35:161-174.
10. Samuels B.L., Bitran J.D. High-dose intravenous melphalan: a review. J Clin Oncol 1995, 13:1786-1799.
11. Harada N., Nagasaki A., Hata H., et al. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake. Acta Haematol 2000, 103:144-151.
12. Moscow J.A., Swanson C.A., Cowan K.H. Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer 1993, 68:732-737.
13. Jurisson S., Cutler C., Smith S.V. Radiometal complexes: characterization and relevant in vitro studies. Q J Nucl Med Mol Imaging 2008, 52:222-234.
14. Marzilli L.G. Linking deprotonation and denticity of chelate ligands. Rhenium(V) oxo analogs of technetium-99m radiopharmaceuticals containing N2S2 chelate ligands. Inorg Chem 1994, 33:4850-4860.
15. Anderson C.J., John C.S., Li Y.J., et al. N, N'-ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and in vivo studies. Nucl Med Biol 1995, 22:165-173.
16. Feldman J.G.R., Mark S., Schwartz J., et al. A methematical model for tumor volume evaluation using two-dimensions. J Appl Quan Meth 2009, 4:8.
17. Kong F.L., Zhang Y., Ali M.S., et al. Synthesis of (99m)Tc-EC-AMT as an imaging probe for amino acid transporter systems in breast cancer. Nucl Med Commun 2010, 31:699-707.
18. Yanagida O., Kanai Y., Chairoungdua A., et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001, 1514:291-302.
19. Shikano N., Kawai K., Nakajima S., et al. Renal accumulation and excretion of radioiodinated 3-iodo-alpha-methyl-L-tyrosine. Ann Nucl Med 2004, 18:263-270.
20. Amano S., Inoue T., Tomiyoshi K., et al. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med 1998, 39:1424-1427.
21. Bergstrom J., Furst P., Noree L.O., et al. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol 1974, 36:693-697.
22. Lin J., Raoof D.A., Thomas D.G., et al. L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia 2004, 6:74-84.
23. He B., Frey E.C. Comparison of conventional, model-based quantitative planar, and quantitative SPECT image processing methods for organ activity estimation using In-111 agents. Phys Med Biol 2006, 51:3967-3981.
24. Pereira J.M., Stabin M.G., Lima F.R., et al. Image quantification for radiation dose calculations-limitations and uncertainties. Health Phys 2010, 99:688-701.